Strain Name |
C57BL/6-Tgfb1tm1Bcgen/Bcgen |
Stock No. | 110164 |
Common name |
B-Tgfb1 cKO mice |
Gene symbol and name | Tgfb1(transforming growth factor, beta 1), Tgfb |
Strain of origin |
C57BL/6 |
Chromosome | 7 |
Coat color | Black | Dietary information | Growth and reproduction diet for experimental mice |
NCBI Gene ID |
21803 |
Application
Gene editing strategy
A designed targeting vector containing 5’-homologous arm, loxP-Exon2-frt-Neo-frt-loxP, 3’-homologous arm, and DTA selection marker was introduced into C57BL/6 ES cells, replacing corresponding Tgfb1 exon 2 locus. The resulting chimeric animals were crossed to C57BL/6 mice to establish the colony.
Phenotype Analysis
TGFb1 produced by myeloid cells is required for GEMsmediated immunomodulation. Tgfb1f/fLysM-Cre and Tgfb1+/+LysMCre mice were gavaged with GEMs before the subsequent experiment.a Flow cytometry analysis of Foxp3 expression in CD4+ T cells in the MLN, IEL, and LPL. Bar graph shows data from three experiments combined. b RNA was extracted from the small intestines of indicated mice, and the expression level of IL-10 was assayed by qRT-PCR. c CD11c+ DCs were purified from the MLNs of GEM-treated Tgfb1f/fLysM-Cre and Tgfb1+/+LysM-Cre mice and incubated with naïve CD4+ T cells in Treg-polarizing condition. Numbers indicate the percentages of CD4+Foxp3+ T cells after 4 days co-culture. Bar graph shows data from three experiments combined. d–f Tgfb1f/fLysM-Cre and Tgfb1+/+LysMCre mice were gavaged with GEMs before DSS administration. d Body weight. e Colons length. f Representative images of H&E staining. g Tgfb1f/fLysM-Cre and Tgfb1+/+LysM-Cre mice were treated with GEMs before H. felis administration. Colonization of H. felis in the gastric tissue was measured by qRT-PCR.
(source: Zeng Z et al.,2019)
Reference
1. Shull MM; Ormsby I; Kier AB; Pawlowski S; Diebold RJ; Yin M;
Allen R; Sidman C; Proetzel G; Calvin D; Annunziata N; Doetschman T. 1992.
Targeted disruption of the mouse transforming growth factor-beta 1 gene results
in multifocal inflammatory disease. Nature 359(6397):693-9. [PMID: 1436033]
2. Boivin GP; O'Toole BA; Orsmby IE; Diebold
RJ; Eis MJ; Doetschman T; Kier AB. 1995. Onset and progression of pathological
lesions in transforming growth factor-beta 1-deficient mice. Am J Pathol
146(1):276-88. [PMID: 7856734]
3. Engle SJ; Ormsby I; Pawlowski S; Boivin
GP; Croft J; Balish E; Doetschman T. 2002. Elimination of Colon Cancer in
Germ-free Transforming Growth Factor Beta 1-deficient Mice. Cancer Res
62(22):6362-6. [PMID: 12438215]